Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Thyroid Gland Carcinoma”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)UnknownNCT01118065
What this trial is testing

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Leiden University Medical Center 42
Early research (Phase 1)Study completedNCT00027534
What this trial is testing

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Breast CancerColorectal CancerGallbladder Cancer+6 more
Michael Morse, MD 14
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06848920
What this trial is testing

Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid Carcinoma (DTC)Neoadjuvant Therapy
Zhejiang University 20
Not applicableActive Not RecruitingNCT02185560
What this trial is testing

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

Who this might be right for
Thyroid Carcinoma
Bayer 453
Early research (Phase 1)Study completedNCT00004074
What this trial is testing

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Who this might be right for
Advanced Adult Primary Liver CancerAnaplastic Thyroid CancerBone Metastases+124 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Study completedNCT00784303
What this trial is testing

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Who this might be right for
Thyroid Cancer
Eisai Inc. 117
Not applicableStudy completedNCT02430714
What this trial is testing

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Who this might be right for
Thyroid Neoplasms
Eisai Co., Ltd. 629
Testing effectiveness (Phase 2)WithdrawnNCT04106843
What this trial is testing

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Who this might be right for
Locally Advanced Adrenal Gland PheochromocytomaLocally Advanced ParagangliomaMetastatic Adrenal Gland Pheochromocytoma+11 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Early research (Phase 1)Study completedNCT00005842
What this trial is testing

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 24
Not applicableApproved For MarketingNCT01683110
What this trial is testing

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Exelixis
Post-approval studies (Phase 4)Study completedNCT01496313
What this trial is testing

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Sanofi 81
Early research (Phase 1)Active Not RecruitingNCT01947023
What this trial is testing

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Who this might be right for
Metastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Looking for participantsNCT05668962
What this trial is testing

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Who this might be right for
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
Massachusetts General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00389441
What this trial is testing

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Pfizer 52
Not applicableApproved For MarketingNCT04204928
What this trial is testing

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid Cancer
Blueprint Medicines Corporation
Early research (Phase 1)Ended earlyNCT02628535
What this trial is testing

Safety Study of MGD009 in B7-H3-expressing Tumors

Who this might be right for
MesotheliomaBladder CancerMelanoma+10 more
MacroGenics 67
Testing effectiveness (Phase 2)Study completedNCT01661179
What this trial is testing

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Who this might be right for
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Genzyme, a Sanofi Company 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT05620134
What this trial is testing

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
CancerTumor, SolidAdvanced Solid Tumor+19 more
Salubris Biotherapeutics Inc 263
Load More Results